ArticleNPJ breast cancer2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Lorna Hopcroft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.